NASDAQ:ALNY - Nasdaq - US02043Q1076 - Common Stock - Currency: USD
Overall ALNY gets a fundamental rating of 4 out of 10. We evaluated ALNY against 555 industry peers in the Biotechnology industry. The financial health of ALNY is average, but there are quite some concerns on its profitability. ALNY is valued quite expensive, but it does show an excellent growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -6.4% | ||
ROE | -233.64% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 86.01% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 8.88 | ||
Debt/FCF | N/A | ||
Altman-Z | 4.95 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.04 | ||
Quick Ratio | 2.98 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 349.54 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
331.91
+2.14 (+0.65%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 349.54 | ||
P/S | 18.43 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 374.91 | ||
P/tB | 374.91 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -6.4% | ||
ROE | -233.64% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 86.01% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 8.88 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 52.6% | ||
Cap/Sales | 1.29% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 3.04 | ||
Quick Ratio | 2.98 | ||
Altman-Z | 4.95 |